Innate Pharma Says That Interim Efficacy Results From TELLOMAK Phase 2 Study In Advanced Mycosis Fungoides, According To Updated Lymph Node Classification, Confirm Clinical Activity And Favorable Safety Profile Of Lacutamab, Shows Updated ORR Of 42.9%
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma announced interim efficacy results from the TELLOMAK Phase 2 study in advanced mycosis fungoides, confirming clinical activity and a favorable safety profile of Lacutamab with an updated ORR of 42.9%.
June 16, 2023 | 8:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's TELLOMAK Phase 2 study shows positive interim efficacy results for Lacutamab in advanced mycosis fungoides, indicating potential growth for the company.
The positive interim efficacy results from the TELLOMAK Phase 2 study indicate that Lacutamab has a favorable safety profile and clinical activity in advanced mycosis fungoides. This could lead to increased demand for the drug and potential growth for Innate Pharma, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100